Key result
Immunization with DL39-VLPs significantly reduced clinical symptom scores (p<0.001), viral shedding, and viremia in cats challenged with feline calicivirus compared to controls.
Why the study?
Vaccination is the primary means of preventing feline calicivirus infection, but traditional inactivated or attenuated vaccines theoretically pose potential safety concerns.
Does DL39-VLPs vaccine reduce clinical symptoms and viral shedding in cats challenged with feline calicivirus?
Does DL39-VLPs vaccine reduce clinical symptoms and viral shedding in cats challenged with feline calicivirus?
p-value: p=<0.001
The DL39-VLPs vaccine candidate safely and effectively protects cats against both GI and GII genotypes of feline calicivirus, significantly reducing clinical symptoms and viremia.
DL39-VLPs merit preclinical immunogenicity testing in cats; leaves open whether they outperform current vaccines in field settings.
Feline calicivirus (FCV) is one of the most widespread pathogens affecting feline animals. Currently, FCV is believed to be divisible into two genotypes, with prevalent strains encompassing both GI and GII. Vaccination is the primary means of preventing FCV infection, yet traditional inactivated or attenuated vaccines theoretically pose potential safety concerns. In this study, a virus-like particles (VLPs), named DL39-VLPs, was constructed, using the VP1 gene of FCV DL39 strain with broad neutralizing and protective properties as a template through insect cell expression system. Cats were immunized with a 50 μg dose of DL39-VLPs mixed with an oily adjuvant via subcutaneous injection in the neck. For feline antisera positive for DL39-VLPs, the titer range in neutralization tests against prevalent GI strains ranged from 1:151 to 1:538, whereas the titer range in neutralization tests against prevalent GII strains was between 1:65 and 1:113. Challenge trials demonstrated that cats immunized with DL39-VLPs exhibited no significant clinical symptoms and had significantly reduced viral shedding and viremia compared to the challenged control group. Ultimately, a safe and highly protective VLP vaccine candidate, DL39-VLPs, was developed, which provides an important tool for the prevention and control of FCV infection.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied Feline calicivirus infection (n=15). DL39-VLPs vs. Adjuvant and DMEM was evaluated on Clinical symptom scores (p=<0.001). Immunization with DL39-VLPs significantly reduced clinical symptom scores (p<0.001), viral shedding, and viremia in cats challenged with feline calicivirus compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: